Edition:
United States

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

155.80GBp
11:38am EDT
Change (% chg)

-1.80 (-1.14%)
Prev Close
157.60
Open
159.70
Day's High
159.70
Day's Low
153.00
Volume
1,991,415
Avg. Vol
1,752,410
52-wk High
179.00
52-wk Low
122.90

Latest Key Developments (Source: Significant Developments)

Vectura posts 9-month loss before taxation of 40.1 million stg
Tuesday, 21 Mar 2017 03:28am EDT 

Vectura Group Plc : Nine-Month pretax loss 40.1 million stg versus loss of 1.9 million stg for 12 months ended March 31, 2016 . 9-month revenue 126.5 million stg . 9-month basic loss per share 5.3 pence . Sees 2018 capex of GBP 10 million - GBP 15 million . Targets annual synergy savings of at least £10 million by 2018 .Sees 2017 capex of GBP 15 million - GBP 20 million.  Full Article

Vectura signs deal with Mundipharma on respiratory treatments
Friday, 23 Dec 2016 02:16am EST 

Vectura Group Plc : Global development programme with Mundipharma for PMDI inhaled triple therapy (VR2076) for asthma and COPD . Exercise of this option triggers a payment to vectura of eur 1.5 million . If Mundipharma decides to develop programme in COPD, Vectura eligible for further potential milestones of up to eur 20.0 million . In December 2015, companies entered into a feasibility and option agreement .Further total potential milestone payments up to eur 46.5 million are receivable linked to milestones, future net sales of product.  Full Article

Vectura's first-half pretax loss widens to 18.6 million
Wednesday, 23 Nov 2016 02:00am EST 

Vectura Group Plc :H1 pretax loss -18.6 million stg versus -2.7 million stg loss year ago.  Full Article

Vectura says asthma drug misses primary endpoint in Phase III trial
Tuesday, 30 Aug 2016 02:38am EDT 

Vectura Group Plc : Update on Mundipharma's European Phase III trial of flutiform ® in COPD and latest flutiform ® in-market sales . Informed by its partner mundipharma that its phase iii trial of flutiform ® did not meet primary endpoint . Mundipharma is currently undertaking an analysis of trial's other endpoints .Mundipharma has indicated that primary endpoint result will not allow it to make a regulatory filing for COPD indication in Europe.  Full Article

Vectura says asthma drug misses primary endpoint in Phase III trial
Tuesday, 30 Aug 2016 02:37am EDT 

Vectura Group Plc : Has been informed by its partner Mundipharma that its phase III trial of flutiform® did not meet primary endpoint .Mundipharma is currently undertaking an analysis of trial's other endpoints but has indicated that primary endpoint result will not allow it to make a regulatory filing for copd indication in europe..  Full Article

Vectura initiates legal proceedings against GSK in the U.S.
Wednesday, 27 Jul 2016 12:19pm EDT 

Vectura Group Plc : Vectura initiates legal proceedings against GlaxoSmithKline Plc (GSK) . Vectura has filed a patent infringement lawsuit against GSK claiming infringement of Vectura's U.S. patents in Delaware district court . Continues to remain open to finding a mutually acceptable solution in order to avoid costs and potential uncertainty over royalties that have, up to now, been subject to a cap of 13 mln stg per calendar year . Separate licence agreement with GSK relating to legacy Skyepharma dry powder formulation technology used in Ellipta products is unaffected .Despite notification from GSK, directors believe that revenues for current financial year ending December 2016 remain in line with current expectations.  Full Article

Vectura says Ablynx to exercise a license option on Fox device
Tuesday, 28 Jun 2016 04:57am EDT 

Vectura Group Plc :Ablynx to exercise option to license Vectura's Fox device for use in its forthcoming phase IIB efficacy study of its inhaled anti-rsv nanobody.  Full Article

Skyepharma sayas High Court of Justice sanctions scheme on merger
Thursday, 9 Jun 2016 05:54am EDT 

Skyepharma Plc :High court of justice in england and wales made an order sanctioning scheme on merger with vectura.  Full Article

Vectura FY core earnings rise 43 pct
Thursday, 26 May 2016 02:17am EDT 

Vectura Group Plc : FY revenues up 24% to £72.0m (2014/15: £58.0m) .EBITDA(1) up 43% to £23.2m (2014/15: £16.2m).  Full Article

Vectura & Propeller Health announce collaboration
Tuesday, 24 May 2016 02:28am EDT 

Vectura Group Plc : Vectura & propeller health announce collaboration .Vectura and propeller health announce collaboration to develop digitally-connected inhalers to address chronic respiratory diseases.  Full Article

More From Around the Web

BRIEF-Vectura posts 9-month loss before taxation of 40.1 million stg

* Nine-Month pretax loss 40.1 million stg versus loss of 1.9 million stg for 12 months ended March 31, 2016